It reduces plasma SAP concentration by more than 95% for as long as the drug is administered [66] and thereby removes all detectable SAP from the CSF in patients with AD [3] and from the brain in human SAP transgenic AD model mice [67]. This evidence concerns the gene APCS and Alzheimer disease.